ArticleEuropean radiology experimental2025
Breast cancer assessment under neoadjuvant systemic therapy using thoracic photon-counting detector computed tomography in prone position: a pilot study.
Article in European radiology experimental, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Photon-counting detector CT in oncology: a new era of cancer imaging.Insights into imaging · 2026Review
- Spectral ultrahigh-resolution photon-counting CT for coronary stent imaging: evaluation in a dynamic phantom.European radiology experimental · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate assessment of treatment response to neoadjuvant systemic therapy (NAST) in breast cancer is important prior to surgery. We aimed at evaluating the feasibility of thoracic photon-counting detector computed tomography (PCCT) in assessing treatment response in breast cancers following NAST.
methodsWe retrospectively included patients with newly diagnosed breast cancer who received contrast-enhanced thoracic PCCT in prone position before and after NAST. Three experienced radiologists measured tumor size, tumor area, iodine uptake within tumors, number of suspicious breast lesions and of suspicious axillary lymph nodes before and after NAST. We compared the initial tumor size to contrast-enhanced magnetic resonance imaging (MRI), the residual tumor size after NAST to histopathology.
resultsEighteen PCCT exams in nine patients aged 58 ± 14 years (mean ± standard deviation) were analyzed. After NAST, PCCT correctly identified a reduction in tumor burden in 9 of 9 cases and a complete response in 2 of 2 cases, with a significant reduction in tumor size, area, T-stage, number of suspicious breast lesions and of suspicious lymph nodes (p < 0.001 for all) as well as reduction in cutaneous infiltration (p = 0.010). Mean and maximum iodine uptake showed a nonsignificant reduction in cases with residual tumor after NAST (p = 0.092 and 0.363).
conclusionThese preliminary findings suggest that thoracic PCCT can accurately detect local changes in breast cancer after NAST. RELEVANCE STATEMENT: Thoracic PCCT offers promising potential for accurately assessing breast cancer response to NAST.
trial registrationGerman Clinical Trials Register DRKS00028997. KEY POINTS: Prone thoracic contrast-enhanced photon-counting detector computed tomography (PCCT) can accurately detect reductions in tumor size, area, and T-stage. Prone PCCT can identify a decrease in the number of suspicious axillary lymph nodes. This technique shows promising results in identifying breast cancer response to neoadjuvant systemic therapy (NAST).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.